PART 1 | Citation and commencement |
| 1. These Regulations are the Infectious Diseases (COVID-19 Clearance) Regulations 2021 and come into operation on 24 April 2021. [S 991/2021 wef 01/01/2022] [S 796/2022 wef 10/10/2022] |
2.—(1) In these Regulations, unless the context otherwise requires —“approved test” means any of the following tests carried out in Singapore in relation to an individual, the purpose of which is to test for the presence of SARS-CoV-2 in that individual:| (a) | a polymerase chain reaction test; | | (b) | an antigen rapid test; |
|
“approved test provider” means a person —| (a) | who has an approval under the Infectious Diseases (Antigen Rapid Test Providers) Regulations 2021 (G.N. No. S 267/2021) to provide, in the course of business at any premises in Singapore, a service involving the carrying on of any approved test for hire or reward; or | | (b) | to whom a licence is issued under the Private Hospitals and Medical Clinics Act (Cap. 248) to carry on any approved test for hire or reward at any premises in Singapore; |
|
| “approved vaccine” means a vaccine described in the First Schedule; |
“atypical finding for SARS-CoV-2”, for an individual who undergoes an approved test or tests, means a determination by or under the authority of the Director, or by a legally qualified medical practitioner in Singapore, that the individual is neither —| (a) | actively infected with a COVID-19 infection; nor | | (b) | a carrier of COVID-19, |
| despite a report by the approved test provider carrying out the approved test or tests that the individual tests positive for SARS‑CoV‑2; |
[S 590/2021 wef 10/08/2021] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
“cleared status” means —| (a) | a cleared status (general) that is current; or [S 908/2021 wef 01/12/2021] [S 796/2022 wef 10/10/2022] | | (b) | a cleared status (special) that is current; [S 991/2021 wef 01/01/2022] [S 796/2022 wef 10/10/2022] | | (c) | [Deleted by S 796/2022 wef 10/10/2022] |
[S 590/2021 wef 10/08/2021] |
| “cleared status certificate” means a certificate granted by the Director under regulation 6(2), (3), (4), (5) or (5A) or 7A(2), (3) or (4) certifying that the individual specified in the certificate has a cleared status according to that regulation; [S 590/2021 wef 10/08/2021] [S 908/2021 wef 01/12/2021] [S 991/2021 wef 01/01/2022] [S 91/2022 wef 14/02/2022] [S 445/2022 wef 01/06/2022] [S 796/2022 wef 10/10/2022] |
| “cleared status (general)” has the meaning given by regulation 6; [S 991/2021 wef 01/01/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| “cleared status (special)” has the meaning given by regulation 7A; [S 908/2021 wef 01/12/2021] |
| [Deleted by S 55/2023 wef 13/02/2023] |
“corresponding foreign authority” means the government or an appropriate authority of a foreign country that has the functions corresponding to the functions of —| (a) | the Director —| (i) | under these Regulations of certifying that an individual has recovered from a COVID-19 infection in that foreign country; | | (ii) | under the Infectious Diseases (Antigen Rapid Test Providers) Regulations 2021 of authorising a person to provide in that foreign country the services of an approved test provider; or | | (iii) | under the Private Hospitals and Medical Clinics Act 1980 of authorising any premises or conveyance in that foreign country to be used as a private hospital, medical clinic, clinical laboratory or healthcare establishment; or |
| | (b) | the Singapore Medical Council under the Medical Registration Act 1997 of authorising an individual to practise medicine in that foreign country; |
[S 634/2022 wef 29/07/2022] |
| “COVID-19 naïve individual” means an individual who is not a recovered individual; [S 91/2022 wef 14/02/2022] |
| “current”, for any cleared status, has the meaning given by regulation 8A; [S 590/2021 wef 10/08/2021] |
“defined approved vaccine” means —| (a) | Sinopharm COVID‑19 vaccine; or | | (b) | Sinovac‑Coronavac COVID-19 vaccine; |
[S 991/2021 wef 01/01/2022] |
| “digital cleared status certificate” means a cleared status certificate granted in a digital form described in regulation 4(1); |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| “foreign ART provider” means a person who is duly authorised by a corresponding foreign authority of a foreign country to provide in the foreign country the services of an approved test provider; [S 634/2022 wef 29/07/2022] |
| “foreign country” means any country or territory outside Singapore; [S 634/2022 wef 29/07/2022] |
| “foreign healthcare institution” means any premises or conveyance that is duly authorised by a corresponding foreign authority of a foreign country to be used as a private hospital, medical clinic, clinic laboratory or healthcare establishment in the foreign country; [S 634/2022 wef 29/07/2022] |
| “foreign medical practitioner” means an individual who is duly authorised by a corresponding foreign authority of a foreign country to practise medicine in that foreign country; [S 634/2022 wef 29/07/2022] |
| [Deleted by S 226/2022 wef 29/03/2022] |
| “medical treatment” includes a medical consultation, and a diagnostic procedure connected with any medical treatment; [S 9/2022 wef 06/01/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
“nationwide approved vaccine” means any of the following approved vaccines:| (a) | Tozinameran (Pfizer-BioNTech COVID-19 vaccine or Comirnaty COVID-19 vaccine); | | (b) | Spikevax (Moderna COVID-19 vaccine); [S 69/2022 wef 01/02/2022] | | (c) | Sinovac‑Coronavac COVID-19 vaccine; | | (d) | COVOVAX COVID-19 vaccine or Nuvaxovid (Novavax COVID-19 vaccine); [S 445/2022 wef 01/06/2022] |
[S 908/2021 wef 01/12/2021] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 324/2021 wef 16/05/2021] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| “primary vaccination” means undergoing a vaccination after which the individual vaccinated is eligible to be granted under regulation 6(4) a certificate stating that he or she has a cleared status (general) for a definite period of at least 270 days; [S 91/2022 wef 14/02/2022] [S 445/2022 wef 01/06/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| “recognised medical practitioner”, for any provision of these Regulations, means a legally qualified medical practitioner in Singapore approved by the Director for the purposes of that provision in these Regulations; |
| “recognised vaccination provider”, in relation to an approved vaccine, means an individual or a body approved by or accredited with the Government, in relation to the approved vaccine, to administer it for the purposes of these Regulations; [S 590/2021 wef 10/08/2021] |
“recovered individual” means an individual who —| (a) | tests positive for SARS-CoV-2 upon undergoing (whether before, on or after 24 April 2021) any of the following:| (i) | a polymerase chain reaction test in or outside Singapore; | | (ii) | an antigen rapid test in Singapore on or after 6 January 2022, and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection; | | (iii) | an antigen rapid test outside Singapore, where the result is certified by a corresponding foreign authority, foreign medical practitioner, foreign healthcare institution or foreign ART provider; | | (iv) | an antigen rapid test outside Singapore (where the result is not certified in accordance with sub-paragraph (iii)), and a subsequent serology test in Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection; | | (v) | a serology test in or outside Singapore that is not attributable to the administration of any vaccine against a COVID-19 infection, without having tested positive for SARS-CoV-2 upon undergoing a polymerase chain reaction test or an antigen rapid test; | | (vi) | an antigen rapid test in Singapore on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms; | | (vii) | an antigen rapid test in Singapore (whether before, on or after 23 February 2022) that is performed by or under the direction of an approved test provider or is self-administered by the individual under the supervision of an approved test provider; |
| | (b) | is assessed (whether before, on or after 24 April 2021) as having had a COVID-19 infection; and | | (c) | is not actively infected with a COVID-19 infection; |
[S 634/2022 wef 29/07/2022] |
| “relevant assessment activity” means ascertaining the results of an approved test on a respiratory specimen from an individual and recording the results, even if uncertain or invalid; [S 768/2021 wef 11/10/2021] |
| [Deleted by S 326/2022 wef 26/04/2022] |
| “relevant sampling activity” means removing a respiratory specimen from the lining of the oral or nasal passages of an individual where that is being done for the purpose of a relevant testing activity; [S 768/2021 wef 11/10/2021] |
“relevant start date”, in relation to any COVID-19 infection of a recovered individual, means —| (a) | in a case falling within paragraph (a)(v) of the definition of “recovered individual” read with paragraphs (b) and (c) of that definition —| (i) | the date that the individual first tested positive for SARS-CoV-2 upon undergoing the serology test in or outside Singapore that led to the assessment of the individual having the COVID-19 infection; or | | (ii) | such earlier date (if any) that is certified by a registered medical practitioner in Singapore as the date that the individual is first assessed as having had the COVID-19 infection; or |
| | (b) | in any other case — the date that the individual first tested positive for SARS-CoV-2 upon undergoing the test or series of tests under paragraph (a)(i), (ii), (iii), (iv), (vi), or (vii) of the definition of “recovered individual”, which led to the assessment of the individual having the COVID-19 infection; |
[S 634/2022 wef 29/07/2022] |
| “relevant testing activity” means subjecting the respiratory specimen from an individual to an approved test for the purpose of testing the presence of SARS-CoV-2 in that individual; [S 768/2021 wef 11/10/2021] |
| “respiratory specimen” includes human biological tissue, saliva or mucus; |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 326/2022 wef 26/04/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 326/2022 wef 26/04/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 69/2022 wef 01/02/2022] |
| “treating doctor”, for an individual, means a legally qualified medical practitioner who, in the course of providing medical treatment of the individual as a patient thereof, assesses the individual’s condition, whether remotely or in person; [S 9/2022 wef 06/01/2022] |
| “Type S recovered individual” means a recovered individual because he or she tested positive for SARS-CoV-2 upon undergoing a test mentioned in paragraph (a)(v) of the definition of “recovered individual”; [S 91/2022 wef 14/02/2022] [S 634/2022 wef 29/07/2022] |
| “Type T recovered individual” means a recovered individual because he or she tested positive for SARS-CoV-2 upon undergoing a test mentioned in paragraph (a)(i), (ii), (iii), (iv), (vi) or (vii) of the definition of “recovered individual”; [S 91/2022 wef 14/02/2022] [S 102/2022 wef 24/02/2022] [S 634/2022 wef 29/07/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| “vaccinated” means vaccinated against a COVID‑19 infection by a recognised vaccination provider using (whether before, on or after 10 August 2021) an approved vaccine or a combination of approved vaccines in the way described in the First Schedule. [S 324/2021 wef 16/05/2021] [S 513/2021 wef 12/07/2021] [S 590/2021 wef 10/08/2021] [S 908/2021 wef 01/12/2021] [S 796/2022 wef 10/10/2022] |
| [Deleted by S 796/2022 wef 10/10/2022] |
| [Deleted by S 324/2021 wef 16/05/2021] |
| (2) For the purposes of these Regulations, an individual is treated as undergoing or having undergone an approved test where an approved test is applied to any respiratory specimen taken from the individual in the course of a relevant sampling activity. |
| (3) In reckoning a period for the purposes of these Regulations, days must be counted consecutively, whether or not a public holiday. |
| (4) To avoid doubt, for the purpose of determining whether an individual is vaccinated, any amendment to the First Schedule which inserts, or deletes and substitutes, any vaccine in the First Schedule applies in relation to any individual who is administered that vaccine even before the date the amendment to that Schedule comes into operation. [S 908/2021 wef 01/12/2021] |
| (5) [Deleted by S 474/2022 wef 14/06/2022] |
| (6) [Deleted by S 796/2022 wef 10/10/2022] |
|
| 3. [Deleted by S 796/2022 wef 10/10/2022] |
| Digital certificates and automated decision making, etc. |
| 4.—(1) To avoid doubt, a cleared status certificate may be granted under these Regulations in a digital form, consisting of evidence of the grant of the certificate (using information about the individual to whom the certificate relates) that is displayed on a mobile communication device or other electronic device. [S 317/2022 wef 19/04/2022] [S 474/2022 wef 14/06/2022] (2) For the purposes of these Regulations, any decision, assessment or certification which may be made or granted by the Director under any provision in these Regulations may also be made or granted —| (a) | by a public officer or other individual acting under the authority of the Director; or | | (b) | by a computer for whose operation the Director or a public officer mentioned in sub‑paragraph (a) is responsible. |
|
|
| 5. [Deleted by S 796/2022 wef 10/10/2022] |
|
